StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $1.12 | $1.09 | -2.68% | 0.1M |
| 05-08 | $1.12 | $1.11 | -0.89% | 4.9M |
| 05-11 | $1.07 | $1.11 | +3.74% | 0.4M |
| 05-12 | $1.11 | $1.12 | +0.95% | 0.1M |
| 05-13 | $1.13 | $1.07 | -5.31% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Press releases, AI summaries, and links to free transcript sources. Audio webcasts live on the issuer's IR site.
Press releases served direct from sec.gov. Stonvex doesn't host transcript bodies — these require the publisher's terms.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-8.28M | $-6.26M | $-4.78M | $-2.73M |
Net Income | $-8.23M | $-6.24M | $-2.05M | $-2.71M |
EPS (Diluted) | $-1.23 | $-1.17 | $-0.98 | $-0.59 |
Total Assets | $3.41M | $6.15M | $2.09M | $2.17M |
Total Liabilities | $2.52M | $3.52M | $3.98M | $3.69M |
Cash & Equivalents | $2.50M | $5.29M | $980.00K | $949.00K |
Free Cash Flow OCF − CapEx | $-7.44M | $-4.94M | $-3.27M | Not available |
Shares Outstanding | 10.76M | 10.61M | 5.50M | 4.68M |
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).